The Fire Drill
![Image](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjTq1bF_b7BWFX5zSShFyfrS8Luk7YrgKZ_T3kMhjUKld3RRULlkoOOcXE2bR9WA-lGnnI1wHmM7nNZrPhakFSF_-Nhn9GjOLp1d-knV17gkIBsibpSUVPPkKJfaUMaOmZ_cPZrYTEdxJTa/s1600/15766180_s.jpg)
The Preamble: For the past 22 months, I've been taking Xalkori, an oral targeted chemotherapy, to treat stage 4 adenocarcinoma of the lung caused by a ROS1 mutation. Since being on Xalkori, cancerous tumors in my lung, liver and bones have not only regressed but have stayed, miraculously, stable. I know this because every month I have blood drawn for tests which measure tumor markers, (CEA and CA19-9,) and every three-four months I have CT scans. In the past, I've also blogged a lot about the uncertainty of how long Xalkori will work for me and how incredibly nerve-racking it is to not know when it will stop keeping my cancer at bay. Last September Wynn and I flew to Boston for a patient forum to learn about the next steps in lung cancer treatments for folks with ROS1 mutation driven disease. The information we learned was supposed to be the foundation to build the framework for a plan - what ...